Table 2.
Five- and 10-year relative survival (%) and annual percentage change (APC) among children and AYAs with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and Hodgkin lymphoma (HL) by race, age and era, SEER-9, 1975–2012
| Age and era of diagnosis | White | Black | ||
|---|---|---|---|---|
|
| ||||
| 5-year (95% CI) | 10-year (95% CI) | 5-year (95% CI) | 10-year (95% CI) | |
| ALL, 0–14 years | N = 5497 | N = 517 | ||
| 1975–1981 | 66.0 (62.6–69.1) | 57.7 (54.2–61.0) | 46.0 (33.2–57.9) | 37.9 (25.8–49.8) |
| 1982–1988 | 77.7 (74.9–80.3) | 72.2 (69.1–75.1) | 56.9 (45.4–66.9) | 53.3 (41.9–63.5) |
| 1989–1995 | 84.5 (82.1–86.6) | 80.6 (78.0–82.9) | 74.4 (64.4–81.9) | 68.3 (58.0–76.6) |
| 1996–2002 | 89.6 (87.7–91.2) | 86.8 (84.7–88.7) | 83.5 (75.0–89.3) | 78.1 (68.9–84.8) |
| 2003–2007 | 93.3 (91.3–94.9) | – | 92.0 (82.9–96.3) | |
| APC (95% CI) | 1.37 * (1.08–1.66) | 2.15* (1.59–2.71) | 3.01* (2.09–3.93) | 3.91* (2.29–5.55) |
|
| ||||
| ALL, 15–39 years | N = 2003 | N = 184 | ||
| 1975–1981 | 25.2 (20.2–30.5) | 22.7 (17.9–27.9) | 19.2 (6.0–38.0) | 14.6 (3.6–32.7) |
| 1982–1988 | 38.3 (33.3–43.4) | 33.4 (28.5–38.3) | 27.4 (11.2–46.6) | 18.4 (5.7–36.7) |
| 1989–1995 | 42.8 (37.6–47.8) | 38.5 (33.4–43.5) | 33.6 (18.3–49.6) | 33.6 (18.3–49.6) |
| 1996–2002 | 49.8 (44.7–54.7) | 46.9 (41.7–51.8) | 17.3 (7.0–31.4) | 11.6 (3.7–24.5) |
| 2003–2007 | 57.0 (51.5–62.2) | – | 54.9 (39.1–68.2) | – |
| APC (95% CI) | 3.13* (2.18–4.08) | 3.74* (2.56–4.94) | 1.25 (−0.68–3.22) | −1.26 (−3.19–0.71) |
|
| ||||
| AML, 0–14 years | N = 729 | N = 158 | ||
| 1975–1981 | 22 (15.2–29.6) | 18.7 (12.4–26.0) | 33.4 (13.7–54.6) | 33.4 (13.7–54.6) |
| 1982–1988 | 31.6 (22.9–40.5) | 30.6 (22.1–39.6) | 28.6 (11.7–48.2) | 28.6 (11.7–48.2) |
| 1989–1995 | 45.8 (37.4–53.8) | 44.4 (36.1–52.4) | 48.2 (28.7–65.3) | 44.5 (25.6–61.9) |
| 1996–2002 | 57.4 (49.2–64.8) | 54.8 (46.6–62.3) | 51.5 (34.0–66.5) | 48.9 (31.6–64.1) |
| 2003–2007 | 71.2 (61.2–79.0) | – | 53.6 (33.8–69.9) | – |
| APC (95% CI) | 4.58* (3.69–5.48) | 5.47* (3.83–7.14) | 0.31 (−0.86–1.49) | 0.01 (−1.31–1.35) |
|
| ||||
| AML, 15–39 years | N = 2661 | N = 410 | ||
| 1975–1981 | 15.0 (12.0–18.3) | 12.8 (10.0–16.0) | 13.1 (5.7–23.5) | 11.3 (4.6–21.4) |
| 1982–1988 | 29.3 (25.1–33.5) | 25.4 (21.5–29.5) | 13.2 (6.8–21.8) | 11.9 (5.9–20.4) |
| 1989–1995 | 39.1 (34.6–43.5) | 35.3 (31–39.7) | 27.5 (17.0–39.0) | 27.5 (17.0–39.0) |
| 1996–2002 | 49.9 (45.5–54.1) | 46.7 (42.4–51) | 40.4 (29.7–50.7) | 38 (27.5–48.4) |
| 2003–2007 | 55.1 (49.7–60.2) | – | 37.6 (25.5–49.6) | – |
| APC (95% CI) | 5.10* (4.15–6.06) | 6.67* (5.13–8.22) | 2.07* (0.41–3.75) | 2.55* (0.12–5.04) |
|
| ||||
| HL, 0–14 years | N = 973 | N = 146 | ||
| 1975–1981 | 86.5 (81.2–90.4) | 81.7 (75.8–86.3) | 65.2 (40.4–81.8) | 55.4 (31.5–74.0) |
| 1982–1988 | 88.0 (82.2–92.1) | 84.9 (78.5–89.5) | 88.9 (62.4–97.1) | 88.9 (62.4–97.1) |
| 1989–1995 | 93.0 (87.8–96.0) | 91.5 (85.9–94.9) | ~ | ~ |
| 1996–2002 | 96.2 (92.0–98.2) | 94.8 (90.1–97.3) | 92.1 (71.5–98.0) | 92.1 (71.5–98.0) |
| 2003–2007 | 98.2 (92.7–99.6) | – | 96.0 (74.8–99.4) | – |
| APC (95% CI) | 0.55* (0.29–0.80) | 0.81* (0.39–1.23) | 0.78 (−0.08–1.66) | 2.40* (1.16–3.66) |
|
| ||||
| HL, 15–39 years | N = 12521 | N = 1467 | ||
| 1975–1981 | 85.5 (83.9–87.0) | 78.3 (76.4–80.1) | 79.4 (71.4–85.4) | 66.2 (57.3–73.8) |
| 1982–1988 | 87.3 (85.9–88.6) | 81.9 (80.3–83.4) | 81.5 (75.1–86.5) | 77.3 (70.3–82.9) |
| 1989–1995 | 91.3 (90.1–92.4) | 87.5 (86.0–88.8) | 76.9 (71.5–81.4) | 69.1 (63.2–74.2) |
| 1996–2002 | 93.5 (92.4–94.5) | 91.1 (89.7–92.3) | 84.0 (79.4–87.7) | 80.5 (75.5–84.6) |
| 2003–2007 | 96.4 (95.3–97.3) | – | 92.0 (87.6–94.9) | – |
| APC (95% CI) | 0.44* (0.37–0.51) | 0.73* (0.61–0.86) | 0.38* (0.13–0.63) | 0.53 (−0.06–1.12) |
*
, APC is significant at P< 0.05; -, Survival estimate not available due to insufficient number of patients
APC for 5-year survival was calculated based on data from 1975–2007; APC for 10-year survival was calculated based on data from 1975–2002.